# Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)

> **NCT00661830** · PHASE2 · COMPLETED · sponsor: **PD Dr Markus Möhler** · enrollment: 103 (actual)

## Conditions studied

- Adenocarcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Placebo
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00661830
- **Lead sponsor:** PD Dr Markus Möhler
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2013-11-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00661830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00661830, "Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00661830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*